VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 200 filers reported holding VAXCYTE INC in Q4 2022. The put-call ratio across all filers is 0.72 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $68,453,446 | -15.1% | 1,342,751 | -16.8% | 2.28% | -2.1% |
| Q2 2023 | $80,609,253 | +83.8% | 1,614,122 | +38.0% | 2.33% | +80.2% |
| Q1 2023 | $43,851,600 | -21.8% | 1,170,000 | 0.0% | 1.30% | -17.8% |
| Q4 2022 | $56,101,500 | +234.2% | 1,170,000 | +37.6% | 1.58% | +642.9% |
| Q1 2021 | $16,787,000 | -25.7% | 850,000 | 0.0% | 0.21% | -12.4% |
| Q4 2020 | $22,585,000 | -46.2% | 850,000 | 0.0% | 0.24% | -60.5% |
| Q3 2020 | $41,973,000 | +56.2% | 850,000 | 0.0% | 0.61% | +40.9% |
| Q2 2020 | $26,869,000 | – | 850,000 | – | 0.44% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |